BEBT-109

BEBT-109 is an oral, small molecule pan-mutant-selective inhibitor of the epidermal growth factor receptor (EGFR). It is designed to target a broad spectrum of EGFR mutations, including T790M and exon 20 insertion mutations that are commonly associated with resistance to earlier-generation EGFR inhibitors in non-small cell lung cancer (NSCLC). Preclinical and early clinical studies have demonstrated promising antitumor activity and an acceptable safety profile. The drug has shown efficacy in patients with advanced or refractory NSCLC harboring EGFR T790M or exon 20 insertion mutations, with objective response rates around 44% and median progression-free survival of approximately 8 months. Common adverse events include diarrhea, rash, and anemia. BEBT-109 is being developed by BeBetter Med as a new molecular entity for the treatment of NSCLC[1][3][5][9].

Other names

BEBT109BEBT-109BEBT 109